Silo Pharma is embarking on a preclinical toxicity study of its novel time-released, dosage-controlled formulation of ketamine – SP-26 – for the treatment of fibromyalgia.
Researchers from Inserm, CNRS, Sorbonne University and clinicians from the AP-HP and at Paris Brain Institute identified one of the mechanisms explaining ketamine effect as an...
Silo Pharma is preparing a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA) for a novel topical...
Chief clinical development officer of HMNC Brain Health, Hans Eriksson, speaks to Psychedelic Health about how the company’s formula, ‘Ketabon’, will provide the therapeutic benefits of ketamine without...
Results from a new study suggest that the antidepressant effects of ketamine can be prolonged in people with treatment-resistant depression through computer-based neurocognitive training.
Results from a small study suggest that low-dose ketamine could be an effective treatment for children living with ADNP syndrome, otherwise known as Helsmoortel-VanDerAa syndrome.
New study findings have shown that mice respond more to the antidepressant effects of the drug ketamine when administered by men and not by women.
Awakn Life Sciences has signed the twelve month option agreement with a drug development company that will see its ketamine formulation and route of administration optimised...
Awakn Life Sciences has signed its first licensing partnership agreement in Canada with Ontario-based Wellbeings Pain Management and Dependency Clinic, which is focused on multi-disciplinary, evidence-based,...
Awakn Life Sciences is expanding its commercial operations into the US through its first licensing partnership with Revitalist Lifestyle and Wellness – one of the largest...
